Specification of illumination requirements is the basic concept of deciding how much illumination is required for a given task. Clearly, much less light is required to illuminate a hallway compared to that needed for a word processing work station. Generally speaking, the energy expended is proportional to the design illumination level. For example, a lighting level of 400 lux might be chosen for a work environment involving meeting rooms and conferences, whereas a level of 80 lux could be selected for building hallways. If the hallway standard simply emulates the conference room needs, then much more energy will be consumed than is needed. Unfortunately, most of the lighting standards even today have been specified by industrial groups who manufacture and sell lighting, so that a historical commercial bias exists in designing most building lighting, especially for office and industrial settings.
If it is possible to answer this question, answer it for me (else, reply "unanswerable"): What is a basic concept of deciding how much illumination is required for a given task?
Ah, so.. Specification of illumination requirements

Drug discovery and development is very expensive; of all compounds investigated for use in humans only a small fraction are eventually approved in most nations by government appointed medical institutions or boards, who have to approve new drugs before they can be marketed in those countries. In 2010 18 NMEs (New Molecular Entities) were approved and three biologics by the FDA, or 21 in total, which is down from 26 in 2009 and 24 in 2008. On the other hand, there were only 18 approvals in total in 2007 and 22 back in 2006. Since 2001, the Center for Drug Evaluation and Research has averaged 22.9 approvals a year. This approval comes only after heavy investment in pre-clinical development and clinical trials, as well as a commitment to ongoing safety monitoring. Drugs which fail part-way through this process often incur large costs, while generating no revenue in return. If the cost of these failed drugs is taken into account, the cost of developing a successful new drug (new chemical entity, or NCE), has been estimated at about 1.3 billion USD(not including marketing expenses). Professors Light and Lexchin reported in 2012, however, that the rate of approval for new drugs has been a relatively stable average rate of 15 to 25 for decades.
If it is possible to answer this question, answer it for me (else, reply "unanswerable"): Who reported the stable average rate in 2007?
Ah, so.. unanswerable

The Premier League distributes a portion of its television revenue to clubs that are relegated from the league in the form of "parachute payments". Starting with the 201314 season, these payments are in excess of 60 million over four seasons. Though designed to help teams adjust to the loss of television revenues (the average Premier League team receives 55 million while the average Football League Championship club receives 2 million), critics maintain that the payments actually widen the gap between teams that have reached the Premier League and those that have not, leading to the common occurrence of teams "bouncing back" soon after their relegation. For some clubs who have failed to win immediate promotion back to the Premier League, financial problems, including in some cases administration or even liquidation have followed. Further relegations down the footballing ladder have ensued for several clubs unable to cope with the gap.
If it is possible to answer this question, answer it for me (else, reply "unanswerable"): If a team is relegated in the Premier League what type of tv payment do they receive?
Ah, so..
The Premier League distributes a portion of its television revenue to clubs that are relegated from the league in the form of "parachute payments".